Bryan, Garnier & Co's News

Read all the news of the independent investment banking dedicated to Growth
Share on
Filters

AstraZeneca: Very encouraging preliminary phase II data for AZD9291 in lung cancer

NEUTRAL, Fair Value  4830p (+19%)

Published last August Monday 24, 2015

Galapagos: Strong cash position...CF pipeline to accelerate

BUY, Fair Value EUR57 (0%)

Published last August Monday 24, 2015

Renewable energy - PV: Doubling of French solar tenders to 800MW

Published last August Friday 21, 2015

Pharmaceuticals: Positive phase III results for Lilly's SGLT-2 inhibitor, Jardiance. Implications for our stock universe

Published last August Friday 21, 2015

Carlsberg: Poor Q2 15 figures

NEUTRAL, Fair Value DKK634 (+7%)

Published last August Wednesday 19, 2015

CNY devaluation: Implications for our luxury sample

Published last August Monday 17, 2015

adidas Group: NBA star James Harden signs 13-year deal with adidas

NEUTRAL, Fair Value EUR79 (+15%)

Published last August Monday 17, 2015

LDR Holding: Acceleration ahead?

BUY, Fair Value USD53 (+31%)

Published last August Monday 17, 2015

LDR Holding: LDR announces capital increase

BUY, Fair Value USD53 (+25%)

Published last August Thursday 13, 2015

Galapagos: This opportunity will self-destruct in 60 days

BUY, Fair Value EUR61 vs. EUR57 (+10%)

Published last August Tuesday 11, 2015

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities